ERBB2 and neoplasm: However, it is worth noting that no definitive conclusion can be drawn from this trial as the number of Her2+ patients was relatively small (48 and 50 in the vaccinated and control group, respectively) and the balancing of the two arms of the trial, in terms of tumor size, hormone and nodal status, should have been more carefully evaluated.